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Summary. This review will focus on new technol-
ogies in development that promise to lead to further
advances in haemophilia therapeutics. There has
been continued interest in the bioengineering of
recombinant factor VIII (rFVIII) and factor IX (rFIX)
with improved function to overcome some of the
limitations in current treatment, the high costs of
therapy and to increase availability to a broader
world haemophilia population. Bioengineered forms
of rFVIII, rFIX or alternative haemostatic molecules
may ultimately have an impact on improving the
efficacy of therapeutic strategies for the haemophilias
by improving biosynthesis and secretion, functional
activity, half-life and immunogenicity. Preventing
and suppressing inhibitors to factor (F) VIII remain a
challenge for both clinicians and scientists. Recent
experiments have shown that it is possible to obtain
anti-idiotypic antibodies with a number of desirable
properties: (i) strong binding avidity to FVIII inhib-
itors; (ii) neutralization of inhibitory activity both in
vitro and in vivo; (iii) cross-reactivity with antibodies
from unrelated patients, and (iv) no interference with
FVIII function. An alternative, although comple-
mentary approach, makes use of peptides derived
from filamentous-phage random libraries. Mimo-
topes of FVIII can be obtained, which bind to the
paratope of inhibitory activity and neutralize their
activity both in vitro and in vivo. In this paper, we
review advanced genetic strategies for haemophilia
therapy. Until recently the traditional concept for
gene transfer of inherited and acquired haematolog-
ical diseases has been focused on how best to obtain
stable insertion of a cDNA into a target-cell genome,
allowing expression of a therapeutic protein. How-
ever, as gene-transfer vector systems continue to
improve, the requirement for regulated gene tran-
scription and hence regulated protein expression will
become more critical. Inappropriate protein expres-
sion levels or expression of transferred cDNAs in
non-intended cell types or tissues may lead to target-
cell toxicity or activation of unwanted host immune
responses. Regulated protein expression requires that
the transferred gene be transferred with its own
regulatory cassette that allows for gene transcription
and translation approaching that of the normal gene
in its endogenous context. New molecular tech-
niques, in particular the use of RNA molecules, now
allow for transcription of corrective genes that mimic
the normal state.
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Coagulation factors bioengineered for improved
haemophilia therapeutics
Current developments in mammalian cell-culture
technology and recombinant protein expression have
enabled the production of recombinant (r)FVIII and
rFIX devoid of any human protein exposure during
the cell culture fermenting process and in final
formulation [1]. However, rFVIII/rFIX replacement
remains a very expensive therapeutic, with the
average patient using up to US$100 000 of
factor concentrate per year [2], and with limited
accessibility to developing countries. The ability to
bioengineer recombinant clotting factors with
improved function holds promise to overcome some
of the limitations in current treatment, the high costs
Correspondence: Dr S. W. Pipe, Pediatrics and Communicable
Diseases, University of Michigan, L2110 Women’s Hospital, 1500
E. Medical Center Drive, Ann Arbor, MI 48109–0238, USA.
Tel.: + 1 734 647 2893; fax: + 1 734 936 7083;
e-mail: ummdswp@med.umich.edu
Haemophilia (2004), 10, (Suppl. 4), 55–63
 2004 Blackwell Publishing Ltd 55
of therapy and increase availability to a broader
world haemophilia population [3,4]. Most research
has been directed at overcoming the inherent limita-
tions of rFVIII expression, and includes techniques to
improve rFVIII biosynthesis and secretion, functional
activity, half-life and antigenicity/immunogenicity
(Table 1). Some of these molecules have already
reached commercialization and have been used in
gene-therapy strategies, while others are being eval-
uated in preclinical studies. Forms of rFIX with
improved functional properties, such as more effi-
cient expression and higher specific activity, have
been investigated in preclinical studies and may also
prove useful in gene-therapy trials for haemophilia B
(Table 1) (reviewed in [5]).
With each strategy, the research approach used has
been, firstly, to understand the limitations in rFVIII
properties and its impact on production and therapy.
Next, key functional regions of the protein are
mapped or better characterized, and then targeted
bioengineering strategies are applied to alter the
properties of that particular rFVIII. This review will
summarize three examples of the application of this
approach.
The best example of a bioengineered molecule to
proceed all the way through these phases is the
development of B-domain deleted (BDD)-FVIII.
Early on in the study of rFVIII expression, it was
demonstrated that the B domain of FVIII, the
equivalent of approximately 38% of the primary
cDNA sequence, could be removed without loss
of FVIII procoagulant activity. This significantly
improved the yield of rFVIII [6,7]. The increased
expression resulted from markedly increased levels
of mRNA and increased translation. The reduced
size of the BDD-FVIII cDNA facilitated packaging
within certain viral vectors. As BDD-FVIII has a
biochemical profile similar to wild-type FVIII [7,8],
there was enthusiasm to adopt it for gene-therapy
strategies. Clinical studies had already shown that
BDD-FVIII provided safe, well-tolerated and effect-
ive treatment for haemophilia A [9]. Most signifi-
cantly, rates of inhibitor formation in previously
untreated patients with haemophilia A were similar
to that observed with full-length rFVIII concen-
trates [10], demonstrating that, despite such a
major modification of the FVIII protein, this bio-
engineered form of FVIII was not more immuno-
genic. In another strategy, a truncated intron-1
sequence of FIX was inserted into BDD-FVIII
cDNA in place of either FVIII introns 1, 12 or 13
[11]. This led to an increase in FVIII secretion that







Increased mRNA expression Removal of entire B domain [6, 7, 8]
Substitution with FIX intron 1 [10]
Reduced ER chaperone interactions Phe309Ser [15]
Improved ER–Golgi transport Short B domain containing variants [17]
Improved functional activity
Increased activation des-(868–1562)-FVIII-HCII [4]






Improved plasma half-life LRP-binding site mutations (A2 domain residues 484–509 and C2 domain) [4, 12]
Heparan sulphate proteoglycans-binding site mutations (A2 domain
residues 558–565)
4,12
Reduced antigenicity Porcine-human hybrids [4]
FIX
Biosynthesis and secretion
Increased mRNA expression ATG triplets as translation initiation
Truncated
FIX intron 1
Reduced collagen IV binding Lys5Ala, Val10Lys
Improved functional activity
Increased specific activity Arg338Ala
FIX-FX hybrids
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was associated with a dramatically higher level of
FVIII mRNA accumulation in the cell. More
recently, investigators have gained insights into
mechanisms that limit rFVIII expression including:
(i) inefficient expression of FVIII mRNA; (ii) ineffi-
cient folding of the primary translation product
within the endoplasmic reticulum (ER) with retent-
ion by chaperone proteins; and (iii) a requirement
for facilitated transport from the ER to the Golgi
apparatus (reviewed in Kaufman et al. [12] and
Soukharev et al. [13]). By understanding the cellu-
lar mechanisms and mapping the key regions of
FVIII, bioengineering strategies have been able to
overcome each of these limitations, and improve
the expression and secretion efficiency of FVIII.
Strategies have included deletion of all or a
significant portion of the B domain to improve
mRNA yield [7,14].
The second approach has involved a hydrophobic
region of the A1 domain of FVIII, mapped as a
putative binding site for immunoglobulin-binding
protein (BiP) [15], a protein chaperone within the
secretion pathway known to bind and retain FVIII
within the ER. Targeted point mutations within the
A1 domain identified conservative mutations (e.g.
Phe309Ser) that could be introduced, leading to
increased FVIII secretion efficiency [16]. In addition,
a facilitated transport system that includes a protein
complex (LMAN1/CFD2), which targets glyco-
protein cargo into secretion vesicles moving from
the ER to the Golgi was identified. This protein
complex appears to interact with its cargo primarily
through interaction with mannose residues on
asparagine (N)-linked oligosaccharides [17]. The
majority of the N-linked oligosaccharides within
FVIII are clustered within the B domain. The
addition of even a small portion of native FVIII B
domain (optimally 226 amino acids with six
N-linked oligosaccharides, 226aa/N6) to BDD-FVIII
produced a 5–10 fold higher secretion efficiency
compared with BDD-FVIII [18]. When the Phe309-
Ser mutation was introduced into 226aa/N6, there
was an additive effect, boosting secretion efficiency
by up to 25-fold compared with BDD-FVIII. The
observations were similar when these novel FVIII
constructs were synthesized in vivo within the
haemophilia A mouse model. Thus these types
of modifications could increase the efficiency
of current commercial rFVIII production, could
be applied to produce rFVIII within transgenic
animals, and could increase the success of gene
therapy applications.
Lastly, for many years it has been recognized that
the thrombin-activated form of FVIII (FVIIIa) is a
heterotrimer of subunits A1 and A2 and a throm-
bin-cleaved light chain. This heterotrimer is unsta-
ble and subject to spontaneous decay of its
procoagulant activity, attributable to dissociation
of its A2 subunit, which occurs at physiological
pH. In addition, recent studies have also shown
that mutations in FVIII that decrease the stability
of the FVIIIa heterotrimer result in haemophilia A
[19,20]. Therefore, as A2 subunit dissociation
limits procoagulant activity in vivo, investigators
have attempted to stabilize the activated form of
FVIIIa to enhance and prolong its procoagulant
activity. An inactivation-resistant FVIII (IR8) was
engineered, which retains the A2 domain covalently
attached to the light chain, thus preventing its
spontaneous dissociation [21]. Additionally, mis-
sense mutations at activated protein C inactivation
cleavage sites provided resistance to further proteo-
lysis of FVIIIa. In vitro, this molecule demonstrated
stability of activity following thrombin activation
and had a markedly higher specific activity. Recent
preclinical studies within the haemophilia A mouse
model demonstrated that IR8 provided more effi-
cient haemostasis than rFVIII at significantly lower
doses of protein infused [22]. Despite its higher
specific activity and stability, it was not observed to
be more thrombogenic in a carotid artery injury
model within the haemophilia A mouse model. In
another strategy, cysteines were substituted at
residues 664 and 1826 within FVIII, successfully
engineering a disulphide bond between the FVIII
A2 and A3 domains to stabilize FVIIIa [23].
Following thrombin activation, the mutant lost
only 20% of its peak activity after 40 min at
22 C as measured by one-stage clotting assay.
During this same incubation time, wild-type FVIIIa
had lost more than 99% of its activity. FVIII
proteins with prolonged activity following throm-
bin activation have the potential of increasing the
efficacy of FVIII in plasma. It is possible that they
may correct haemostasis in vivo at lower levels of
protein, prolonging the activity of FVIIIa even
when FVIII in plasma is present in levels usually
ineffective for haemostasis. For other examples of
bioengineering strategies for clotting factors, see
recent reviews [4,13].
Advanced strategies for inhibitor management
The question of inhibitors to FVIII has continued to
baffle both clinicians and basic scientists, justifying
the intense effort devoted to the design of new
therapeutic approaches to either prevent or suppress
FVIII-specific antibody formation.
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Recent progress made in understanding the mech-
anisms by which an immune response is elicited and
maintained has permitted delineation of a number
of potential non-antigen-specific strategies for the
control of FVIII inhibitors, such as the use of
antibodies to CD40L, B7 molecules or the CD20
B-cell surface marker. Results of such approaches
have brought about much disillusion, attributable to
two main causes: (i) FVIII is a large molecule and
we are far from understanding how an immune
response to it is elicited, especially with regard to
the hierarchy of T-cell epitopes; and (ii) the immune
response to FVIII is highly differentiated, including
high-affinity antibodies with high rate of somatic
mutations and (as extrapolated from observations
made in the haemophilia A mouse model) efficient
memorization. In fact, this situation might represent
the worst scenario for a non-antigen-specific thera-
peutic approach.
Antigen-specific strategies are much more appeal-
ing, in order to prevent any detrimental side-effect on
the immune reactivity of patients, who often already
experience some degree of immunosuppression.
There are basically three possible methods to achieve
an antigen-specific down regulation: make use of
antigen and its derivatives, target specific B cells or
target specific T cells.
Targeting T cells would be very attractive, but, as
stated above, we do not yet know enough about T
cells. A number of key questions are now being
addressed in specialized laboratories to determine
how and when tolerance to FVIII is established,
both centrally and in the periphery, and whether
the T-cell response is amenable to suppression either
directly or indirectly, through, for instance, regula-
tory T cells.
Using the antigen itself or some of its derivatives is
under way. Possibly the best example of this so far is
the use of mutant FVIII molecules in which inhibitor-
binding epitopes have been altered to prevent anti-
body binding, as reported elsewhere.
Choosing B cells as targets for the therapy of
inhibitors carries one main advantage, resulting from
the high specificity and affinity of the B-cell receptor
(BCR) itself. In addition, recent work on signal trans-
duction after ligand binding [24] has demonstrated
that several possibilities by which B cells can be
anergized or even undergo apoptosis exist. However,
a number of obstacles remain to be surmounted
before a BCR-orientated therapy can be launched:
(i) the B-cell pool is continuously replenished over
the entire lifespan, which could render even sophis-
ticated strategies only temporarily successful;
(ii) memorization at the B-cell level makes anergy
induction potentially fragile, as even non-specific
events such as infection can activate memory B cells
and drive them towards plasmocyte differentiation;
and (iii) antibody-secreting plasmocytes located in
the bone marrow essentially downregulate surface
expression of a number of receptors and survive
there for long periods of time.
Notwithstanding this, we are exploring the possi-
bilities of controlling FVIII inhibitors by neutralizing
both their inhibitory activity and production. Our
studies are centred on the use of anti-idiotypic
antibodies and were initiated on the basis of a
number of observations. Firstly, conventional
immune tolerance induction by infusion of large
amounts of FVIII is known to be associated with
induction of anti-idiotypic antibodies [25]. Secondly,
clonal analysis of anti-FVIII human antibodies has
shown that, at least for antibodies towards the C2
domain, a restricted number of VH families are used,
thereby potentially reducing the diversity of the anti-
idiotypic immune response [26]. Thirdly, infusion of
pools of immunoglobulins, known to contain anti-
idiotypic antibodies, results in successful neutraliza-
tion of inhibitors, at least in the acquired form of
haemophilia A [27].
A number of human monoclonal antibodies with
inhibitory properties on FVIII function, and derived
from the natural repertoire of patients’ B memory
cells [28], have been used to generate anti-idiotypic
antibodies. The first of these anti-FVIII antibodies,
BO2C11, has been fully characterized up to its
crystal structure in combination with the C2 domain
[29]. It recognizes the phospholipid-binding site of
C2. Mouse anti-idiotypic antibodies to BO2C11 are
not only capable of neutralizing the inhibitory
activity of the antibody in vitro, but show very
significant neutralization of FVIII activity in haemo-
philia A mice reconstituted with FVIII and BO2C11
[30]. Interestingly, the binding affinity of anti-idio-
typic antibodies to BO2C11 is comparable to the
binding of BO2C11 to FVIII. Thus, a 50% neutral-
ization of FVIII inhibitory activity is obtained by
equimolar concentrations of BO2C11 and its corres-
ponding anti-idiotypic antibody (mAb14C12).
Experiments carried out with anti-FVIII inhibitors
from unrelated patients showed that the idiotype
recognized by mAb14C12 was expressed on specific
antibodies of 50% of patients with anti-C2 inhib-
itors. This raises hope that some anti-idiotypic
reagents will show broad cross-reactivity between
patients.
Anti-idiotypic antibodies have the potential to
downregulate the function of the B-cell clones
expressing the corresponding idiotype, more than
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a mere neutralization of circulating inhibitors.
Experiments are now ongoing to determine whether
engineered antibody molecules could be of use to
target, anergize and possibly induce apoptosis of B
cells carrying the corresponding idiotype. Prelimin-
ary experiments indicate that anti-idiotypic antibod-
ies to anti-A2 inhibitory antibodies could share the
same properties. We are confident that this approach
will lead to a valuable adjunct to the therapy of
patients with inhibitors, alone or in combination
with other forms of therapy.
An alternative, though complementary, approach
has also been followed, which makes use of peptidic
mimotopes derived from filamentous-phage display
libraries [31]. Such short peptides are interesting in
so far as they bind to the paratope of inhibitory
antibodies in a highly specific manner. These mimo-
topes can be designed to differ significantly from the
sequence and/or conformation of the FVIII region
recognized by antibodies and, as such, have little
chance to interfere with FVIII function. Both in
vitro, and in vivo in the haemophilia A mouse model
reconstituted with human rFVIII, such mimotopes
have been shown to successfully neutralize inhibi-
tors. Assuming that increased half-life of such
peptides can be obtained in vivo by making use,
for instance, of d-amino acids or retro-inverso
modification, this therapeutic strategy could be of
help in emergency situations, such as prior to
surgery.
Correction of haemophilia A using RNA repair
The development of molecular repair strategies has
traditionally been viewed as repair of DNA muta-
tions through DNA recombination. Although pro-
gress continues in this area of research, the level of
DNA repair is low and typically requires a selection
step to retrieve corrected cells. Here we describe
a novel approach to correct genetic diseases at
the pre-messenger RNA level through the use of
spliceosome-mediated RNA trans-splicing. Despite
relatively modest levels of repair at the RNA level
and in the absence of selection, in vivo repair of
genetic defects is achieved. Trans-splicing offers
distinct advantages over conventional gene therapy
and in vivo proof of principle has been demonstrated
for haemophilia A.
RNA cis-splicing
The transcription of genes generates precursor
messenger RNAs (pre-mRNAs) that contain exons
and introns. The introns are removed from the
pre-mRNA and the adjacent exons are ligated
together in a highly orchestrated fashion to form
mature meRNA (Fig. 1A). This process, which
occurs within one pre-mRNA, is often called pre-
mRNA cis-splicing and is catalysed by the spliceo-
some [32], an enzymatic complex. The exon–intron
boundaries of pre-mRNA recognized by the spliceo-
some are defined by four conserved cis-elements,
which include: (i) the 5¢ splice site; (ii) the 3¢ splice
site; (iii) the branchpoint; and (iv) the polypyrimi-
dine tract (Fig. 1B). The 5¢ splice site consensus
sequence of U2 introns is AG|GURAGU (where | is
the exon–intron junction). The 3¢ end of the intron
contains the branchpoint, which is poorly conserved
in mammals, with a consensus sequence of YNY-
URAC (the underlined A is termed the branchpoint),
a polypyrimidine tract, which is highly conserved in
mammals, and the 3¢ splice site with a consensus of
YAG|G.
RNA trans-splicing
A second and less well-known form of natural
RNA splicing is called trans-splicing, which occurs
between two independently transcribed RNA
precursors to form composite mRNA (Fig. 1C).
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Fig. 1. Schematic diagram showing two different pathways of pre-
mRNA splicing in eukaryotes. (a) The process of cis-splicing. A
single pre-mRNA here containing three exons (1, 2, 3) and two
introns are spliced together to form mature mRNA. (b) Idealized
structure of a eukaryotic U2 intron showing the four cis-elements
that are responsible for defining the intron–exon boundaries of the
intron. (c) The process of trans-splicing. Exon 1 of the pre-mRNA
from gene A is shown splicing to exon 4 of the pre-mRNA from
gene B. The product of the reaction is a composite message con-
sisting of exon 1 from gene A plus exons 4 and 5 from gene B. Both
processes (cis and trans) are mediated by the spliceosome. BP,
branchpoint; pA, poly A signal; PPT, polypyrimidine tract; SS,
splice site.
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described in species spanning different kingdoms,
but in mammalian cells, trans-splicing is con-
sidered to be rare compared with cis-splicing.
However, the growing list of genes that undergo
trans-splicing, together with a recent computational
study showing that some sequences in public
databases may be the product of trans-splicing
[33], suggests that many more examples will be
discovered.
The ability of mammalian cells to perform RNA
trans-splicing, which was first shown in 1992 [34],
offers the opportunity to alter gene expression at the
RNA level for therapeutic intervention [35]. One
method of trans-splicing using engineered molecules,
termed spliceosome-mediated RNA trans-splicing
(SMaRT), has been described, which is capable of
reprogramming RNA in mammalian cells [36]
(Fig. 2). SMaRT uses specialized constructs called
pre-trans-splicing molecules (PTMs) that are engin-
eered to bind specific pre-mRNAs in the nucleus and
effect a trans-splicing event between the target RNA
and PTM mediated by the spliceosome. Prototype
PTMs comprise three domains (Fig. 3): (i) a binding
domain that is complementary to the target intron
and serves to tether the PTM to a specific location
within the target; (ii) a splicing domain, which
contains splicing elements that are equivalent to
those found in cis-splicing precursors; and (iii) a
coding domain, consisting of an exon or exons that
are trans-spliced to the target. The binding domain
and cis-splicing elements are not retained in the final
modified RNA product. The splicing domain is
designed to maximize trans-splicing activity and
therefore typically contains a potent branchpoint
sequence (UACUAAC), and a long pyrimidine-rich
tract. A typical binding-domain size is 70–150 bases
[37]. The coding sequence can be one or more exons,
a complete coding sequence, or a genomic fragment.
SMaRT reactions result in the simultaneous intro-
duction and removal of RNA sequence from the
target pre-mRNA. As is true for all forms of SMaRT
repair, each PTM need only deliver the defective
portion of the transgene, as opposed to the entire
gene in conventional gene replacement [38]. The
choice of PTM type for any one application
(see below) may be driven by such factors as target
RNA level, type of target, level of conversion
required, or the region of the target that requires
modification.
RNA splicing can correct haemophilia A
SMaRT offers several advantages over conventional
gene therapy: (i) reduction of transgene size, as only a
fragment of the gene is used, allowing application
to large disease genes such as the FVIII gene
(ii) endogenous regulation of the repaired gene, as
the repaired transcript should have the same spatial
and temporal expression pattern as the endogenous
target; (iii) the ability to generate mRNA of normal
length; (iv) a much broader choice of regulatory
sequences; and (v) elimination of ectopic expression
of the transgene because RNA repair is dependent on
the presence of the target.
The usefulness of SMaRT as an RNA-repair
technology has been proven in a variety of models






















from trans-splicing 1 2 X
Fig. 2. Schematic diagram of the process of spliceosome-mediated
RNA trans-splicing (SMaRT). A pre-trans-splicing molecule is
shown binding to the 3¢ splice site an intron in the pre-mRNA
target. A trans-splicing reaction between the 5¢ splice site adjacent
to exon 2 of the target and the 3¢ splice site of the PTM results in a
composite mRNA consisting of exons 1–2 plus coding X. This
process can be made to occur at any exon-intron junction in the
target. BP, branchpoint; pA, poly A signal; PPT, polypyrimidine








Fig. 3. Diagram of a pre-trans-splicing molecule (PTM). The three
main domains in the PTM are a binding domain, a set of splice
elements and a coding unit (X). The sequence between the binding
domain and splice elements is termed a spacer sequence; this is
not absolutely required for efficient trans-splicing. PTMs can be
expressed using any gene delivery system. BP, branchpoint; pA,
poly A signal; PPT, polypyrimidine tract; SS, splice site.
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established that RNA repair by SMaRT was feasible
in mammalian tissue-culture cells and that the level
of repair was significantly higher than was originally
anticipated [36,37,39]. The first in vivo demonstra-
tion of SMaRT was performed in FVIII haemophilia
A knockout mice [40], which were created by
insertion of the neomycin resistance gene in exon
16 of the mouse FVIII gene (F8 E16 knockout mice)
[41]; no functional FVIII protein is detected in these
animals due to the absence of FVIII light chains. For
this study, a PTM was designed to trans-splice to
exon 15 of the endogenous FVIII pre-mRNA target
(just upstream of the exon 16 disruption) and replace
the coding sequence for exons 16–26 (Fig. 4). This
study demonstrated the presence of repaired FVIII
mRNA in the liver of PTM-treated mice, the pres-
ence of circulating FVIII protein, and FVIII activity at
up to 25% of normal over a study period of 8 weeks.
Finally, haemostatic challenge of F8 E16 mice
showed that animals that received a repair PTM
survived a tail clip, whereas all naı̈ve F8 E16
knockout mice or all knockout mice that received a
mutated PTM (trans-splicing incompetent) did not
survive.
Future directions
RNA therapy using SMaRT represents an entirely
new approach to gene therapy, offering the oppor-
tunity to invade an endogenous mutant pre-mRNA
in the nucleus of a diseased cell, precisely excise the
mutated region responsible for the disease and
replace it with a normal coding sequence. This
approach has many advantages compared with
existing conventional gene replacement. SMaRT
coupled with recent advances in viral vectors will
likely offer new therapeutic potential for many
genetic and acquired disorders.
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